Bhopal has taken a significant step in cracking down on begging, with the first FIR filed against both a beggar and an ...

A 52-year-old Angela Nzewi was arraigned before the Children, Sexual and Gender-based Violence Offences Court in Awka, for ...

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...

Alumis (ALUM) stock dropped while Acelyrin (SLRN) stock gained in the premarket as the biopharma companies announced an all-stock merger deal. Read more here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN ...

JAKARTA: Indonesia’s National Alms Agency (Baznas) aims to collect and mobilise Rp750 billion (US$46 million) in charitable funds to reconstruct a range of public facilities in Palestine ...

Design cues from the classic car world often trickle their way into the custom bike realm, and that can be fantastic when they’re executed with great taste. The motorcycle we’re about to look ...

Fintel reports that on January 30, 2025, Oppenheimer initiated coverage of Alumis (NasdaqGS:ALMS) with a Outperform recommendation. Analyst Price Forecast Suggests 356.72% Upside As of January 29 ...

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis ...